Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.

October 25, 2024

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

Clinical Roundup

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.

October 18, 2024

Vol.50 No.39

By Claire Marie Porter

In Brief

Cancer Grand Challenges launches global search to identify cancer’s toughest challenges

A multi-million-dollar global research initiative is bringing together the international scientific community to help identify and tackle the toughest challenges in cancer research, with input from patient advocates.

October 18, 2024

Vol.50 No.39

Guest Editorial

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Having had the honor and pleasure to lead an NCI-designated cancer center for several years, I would like to share my thoughts on this small yet unique set of institutes and their value to NCI and the nation.

October 04, 2024

Vol.50 No.37

By Ze’ev Ronai

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

YOU MAY BE INTERESTED IN

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Cancer Grand Challenges launches global search to identify cancer’s toughest challenges

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Renew today!

Subscriber content

Login

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

YOU MAY BE INTERESTED IN

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Climate change exacerbates cancer disparitiesAmid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Cancer Grand Challenges launches global search to identify cancer’s toughest challenges

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently

Login

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem